Compounds > troglitazone
Page last updated: 2024-11-05

troglitazone and Coronary Artery Disease

troglitazone has been researched along with Coronary Artery Disease in 2 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Coronary Artery Disease: Pathological processes of CORONARY ARTERIES that may derive from a congenital abnormality, atherosclerotic, or non-atherosclerotic cause.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Raji, A1
Plutzky, J1
Takagi, T1
Yamamuro, A1
Tamita, K1
Yamabe, K1
Katayama, M1
Morioka, S1
Akasaka, T1
Yoshida, K1

Reviews

1 review available for troglitazone and Coronary Artery Disease

ArticleYear
Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventions.
    Current cardiology reports, 2002, Volume: 4, Issue:6

    Topics: Adipose Tissue; Animals; Chromans; Coronary Artery Disease; Diabetes Mellitus; Diabetic Angiopathies

2002

Trials

1 trial available for troglitazone and Coronary Artery Disease

ArticleYear
Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus.
    The American journal of cardiology, 2002, Feb-01, Volume: 89, Issue:3

    Topics: Aged; Angioplasty, Balloon, Coronary; Chromans; Coronary Angiography; Coronary Artery Disease; Coron

2002